IP Library Granted Patent US 9,596,852
Granted Patent B2
US 9,596,852 · App. 14/175,193 · Granted Mar 21, 2017

Template-fixed peptidomimetics with antimicrobial activity

Inventors: Steven J. Demarco (Dietgen, CH); Wim Vrijbloed (Moehlin, CH); Ricardo Dias (Binningen, CH); John Anthony Robinson (Wermatswil, CH); Nityakalyani Srinivas (Basel, CH); Frank Gombert (Huttingen, DE); Daniel Obrecht (Baettwil, CH)
Assignees: POLYPHOR LTD.; UNIVERSITAET ZUERICH
A01N43/36C07K1/10C07K7/06C07K7/08C07K7/64C07K14/001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,596,852
App. No.
14/175,193
Granted
Mar 21, 2017
Kind
B2
Abstract

Template-fixed β-hairpin peptidomimetics of the general formula wherein Z is a template-fixed chain of 12 α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa . They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These β-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.

Claims (62)

1. A method of treating a disease or infection caused by a Pseudomonas aeruginosa comprising administering to a subject in need thereof an effective amount of a compound represented by formula (I):

wherein

is D Pro- L Pro or L Pro- D Pro and Z is a chain of 12 α-amino acid residues, wherein the positions of the amino acid residues in the chain are counted starting from the N-terminal amino acid, wherein the amino acid residues in positions P1 to P12 of the chain are:

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Gly, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, D Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, D Val, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Aib, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Abu, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Leu, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ile, Dab;

Thr, Trp, lie, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Nle, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Nva, Dab;

Thr, Trp, lie, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Chg, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Cha, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Gin, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Asp, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Glu, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Thr, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Pro, Dab;

Cit, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Tyr, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, lie, Dab, Lys, Dab, Dab, Tyr, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, His, Trp, Dab, Dab, Ala, Dab;

Ala, Trp, lie, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Ala, Trp, Ile, Dab, Dab, Dab, Dab, Trp, Dab, Dab, Val, Dab;

Thr, Trp, Ile, Lys, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Lys, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Lys, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Lys, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Lys;

Thr, Trp, Ile, Gin, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Gin, Lys, Dab, Dab, Trp, Dab, Dab, Val, Dab;

Thr, Trp, Nle, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Val, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Chg, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Cha, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Hse, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, t-BuG, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Cpa, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Dab, Trp, Dab, Dab, Asn, Dab;

Thr, Trp, Ile, Dab, Lys, Dab, Gin, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Gin, Lys, Dab, Dab, Trp, Dab, Dab, Ala, Gin;

Thr, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Asp, Tyr, Ile, Dab, Lys, D Da, Dab, Trp, Dab, Dab, Ala, Dab;

Asp, Tyr, Ile, Dab, Orn, D Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Glu, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Glu, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Gin;

Glu, Trp, Ile, Dab, Lys, D Dab, Dab, Trp, Dab, Dab, Ala, Dap;

Glu, Trp, Ile, Dab, Orn, D Dab, Dab, Trp, Dab, Dab, Ala, Dab;

Thr, Trp, Ile, Dab, Orn, D Dab, Dab, Trp, Dab, Dab, Ala, Dab; or

Glu, Trp, Ile, Gin, Lys, Dab, Dab, Ser, Dab, Dab, Ala, Ser,

or a pharmaceutically acceptable salt or enantiomer thereof.

2. The method of claim 1 , wherein the subject is suffering from at least one disease selected from the group consisting of respiratory diseases, skin or soft tissue diseases, gastrointestinal diseases, eye diseases, ear diseases, CNS diseases, bone diseases, cardiovascular diseases, gastrourinal diseases, cancer and HIV.

3. The method of claim 1 , wherein the subject is suffering from at least one disease selected from the group consisting of cystic fibrosis, emphysema, asthma, surgical wounds, traumatic wounds, burn wounds, epidemic diarrhea, necrotizing enterocolitis, typhlitis, keratitis, endophthalmitis, otitis, brain abscess, meningitis, osteochondritis, osteomyelitis, endocartitis, pericarditis, epididymitis, prostatitis, urethritis, cancer and HIV.

4. The method of claim 1 , wherein the Pseudomonas aeruginosa bacteria is multi-drug resistant.

5. The method of claim 1 , wherein the compound represented by formula (I) is administered in the form of a pharmaceutical composition and wherein the pharmaceutical composition further comprises at least one member selected from the group consisting of carriers, diluents, excipients and auxiliaries.

6. The method of claim 1 , wherein at least one additional pharmaceutical agent is administered to the subject.

7. The method of claim 6 , wherein the additional pharmaceutical agent is selected from the group consisting of antimicrobial agents, antibiotic agents, anti cancer agents and antiviral agents.

8. The method of claim 1 , wherein the compound of formula (I) is administered topically.

9. The method of claim 1 , wherein the compound of formula (I) is administered by injection.

10. The method of claim 1 , wherein the compound of formula (I) is administered transdermally, transmucosally, orally or by pulmonary administration.

Assignments (3)
SECURITY INTEREST Recorded May 4, 2023
From: ENBIOTIX (SWITZERLAND) GMBH
To: SPRIM GLOBAL INVESTMENTS PTE. LTD
Reel/Frame 063531/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2023
From: DEMARCO, STEVEN J.; VRIJBLOED, WIM; DIAS, RICARDO; ROBINSON, JOHN ANTHONY; SRINIVAS, NIRYAKALYANI; GOMBERT, FRANK; OBRECHT, DANIEL
To: POLYPHOR LTD.; UNIVERSITAET ZUERICH
Reel/Frame 063376/0232 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2023
From: POLYPHOR LTD.
To: ENBIOTIX (SWITZERLAND) GMBH
Reel/Frame 063376/0430 →
Priority Claims (1)
WO PCT/CH06/00036 · Jan 16, 2006 · international
Continuity (2)
Division 12161065
Related Publication 20140187472A1 · Jul 3, 2014